+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy



Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy



Bulletin du Cancer 92(2): E25-E30



This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total beta tubulin, classes I, II and III beta tubulin isotypes, delta2 alpha tubulin, tau protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-beta tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. delta2 alpha tubulin, tau protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p = 0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p = 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 049043498

Download citation: RISBibTeXText

PMID: 15749640


Related references

Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Internal Medicine 48(4): 203-208, 2009

?V-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. British Journal of Cancer 107(5): 823-830, 2012

The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. Plos one 9(4): E93997, 2014

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical Cancer Research 11(15): 5481-5486, 2005

Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clinical Cancer Research 13(3): 994-999, 2007

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62(1): 105-112, 2008

Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Experimental and Therapeutic Medicine 1(3): 445-451, 2010

Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10. Journal of Clinical Oncology 24(18_Suppl): 7051-7051, 2016

ERCC1 and beta tubulin class III (BT-III) expression by quantitative immunofluorescence (IF) in the responder and non-responder group of patients with advanced non-small-cell lung cancer after 2 cycles of cisplatin (P) and vinorelbine (Vn) chemotherapy. Journal of Clinical Oncology 26(15_Suppl): 19065-19065, 2016

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68(3): 478-483, 2010

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. International Journal of Clinical Oncology 18(3): 371-379, 2013

Expression of ERCC1 and class III ß-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy. International Journal of Biological Markers 25(3): 141-149, 2011

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response. Anticancer Research 35(5): 2669-2674, 2015

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1): 9, 2012

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3): 326-333, 2009